- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11.25 | Rapid Micro Biosystems: GrowthDirect-Plattform im Fokus der Wachstumsstrategie | 2 | Investing.com Deutsch | ||
| RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
| 07.11.25 | Rapid Micro Biosystems raises 2025 revenue guidance to at least $33M amid record multi-system order and accelerating margin improvement | 2 | Seeking Alpha | ||
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. Q3 Loss Misses Estimates | 1 | RTTNews | ||
| 07.11.25 | Rapid Micro Biosystems: EPS verfehlt Schätzungen um 0,01 $ - Umsatz besser als erwartet | 3 | Investing.com Deutsch | ||
| 07.11.25 | Rapid Micro Biosystems GAAP EPS of -$0.26 misses by $0.02, revenue of $7.84M beats by $0.24M | 1 | Seeking Alpha | ||
| 07.11.25 | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance | 126 | GlobeNewswire (Europe) | Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual... ► Artikel lesen | |
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.25 | Earnings Outlook For Rapid Micro Biosystems | 4 | Benzinga.com | ||
| 28.10.25 | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Third Quarter 2025 Financial Results on November 7, 2025 | 2 | GlobeNewswire (USA) | ||
| 22.09.25 | Trinity Capital provides $45M in growth capital to Rapid Micro Biosystems | 21 | Seeking Alpha | ||
| 13.08.25 | Stifel bestätigt Kaufempfehlung für Rapid Micro Biosystems und hält an Kursziel von 8 US-Dollar fest | 18 | Investing.com Deutsch | ||
| 13.08.25 | Stifel reiterates Buy rating on Rapid Micro Biosystems stock, maintains $8 target | 2 | Investing.com | ||
| 12.08.25 | Rapid Micro Biosystems reaffirms $32M revenue guidance for 2025 as recurring revenue climbs 15% | 2 | Seeking Alpha | ||
| 12.08.25 | Rapid Micro Biosystems secures $45 million term loan facility | 2 | Investing.com | ||
| 12.08.25 | Rapid Micro Biosystems GAAP EPS of -$0.27, revenue of $7.3M | 1 | Seeking Alpha | ||
| 12.08.25 | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results | 661 | GlobeNewswire (Europe) | Reports second quarter 2025 total revenue of $7.3 million, representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second... ► Artikel lesen | |
| 12.08.25 | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc. | 715 | GlobeNewswire (Europe) | $20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company's financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass.,... ► Artikel lesen | |
| 12.08.25 | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08.25 | A Look Ahead: Rapid Micro Biosystems' Earnings Forecast | 2 | Benzinga.com |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MONTE ROSA THERAPEUTICS | 23,280 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| NUVALENT | 106,82 | +9,78 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,730 | 0,00 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,270 | +4,28 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| ERASCA | 5,170 | 0,00 % | Piper Sandler stuft Erasca mit "Overweight" ein - Kursziel bei 5 US-Dollar | ||
| ALUMIS | 17,920 | 0,00 % | Should You Chase the Rally in Alumis Stock Today? | ||
| AVIDITY BIOSCIENCES | 72,37 | +0,21 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 76,69 | +4,41 % | Wolfe Research stuft Kymera Therapeutics wegen fehlender Impulse herab | ||
| RECURSION PHARMACEUTICALS | 4,860 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| TANGO THERAPEUTICS | 11,790 | 0,00 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Appoints Sung Lee to Board of Directors | ||
| QIAGEN | 40,245 | +0,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 292,53 | 0,00 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| ADMA BIOLOGICS | 18,820 | +2,62 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,680 | +4,49 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,390 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen |
Das Unternehmen RAPID MICRO BIOSYSTEMS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,47 % bei einem Aktienkurs von 3,340 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPID MICRO BIOSYSTEMS INC finden Sie auf Wallstreet Online.